NCT07403136 2026-04-15
Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
Fudan University
Phase 2 Suspended
Clinical Trials
26 trialsNCT05223036 2026-04-13
Testing Obeticholic Acid for Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Phase 2 Suspended
NCT07011550 2026-03-20
Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT05797870 2026-03-19
Lip-Re2
Center Eugene Marquis
Phase 2 Suspended
NCT07071961 2026-02-17
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT05062889 2026-02-03
ERASE-CRC
Gruppo Oncologico del Nord-Ovest
Phase 2 Suspended
NCT05358704 2025-12-04
Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer
Rutgers, The State University of New Jersey
Phase 2 Suspended
NCT05620771 2025-10-20
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
Northwestern University
Phase 2 Suspended
NCT05494697 2025-10-14
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
AIM ImmunoTech Inc.
Phase 2 Suspended
NCT05591534 2025-08-01
ICUREC
University Hospital, Bordeaux
Phase 2 Suspended
NCT05571293 2025-07-30
NEST-1
Weill Medical College of Cornell University
Phase 2 Suspended
NCT06728657 2025-06-18
TORCH-G
Fudan University
Phase 2 Suspended
NCT03722680 2025-04-23
RILUZOX-01
UNICANCER
Phase 2 Suspended
NCT05375708 2025-03-28
SIRIUS
UMC Utrecht
Phase 2 Suspended
NCT04840186 2024-11-12
EXCALIBUR3
Oslo University Hospital
Phase 2 Suspended
NCT06199882 2024-10-15
SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma
Zhejiang Cancer Hospital
Phase 2 Suspended
NCT04090463 2024-05-07
PancFORT
Universita di Verona
Phase 2 Suspended
NCT04084158 2021-02-23
A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
Zhejiang Cancer Hospital
Phase 2 Suspended
NCT03779100 2019-01-28
Lenvatinib Plus PD-1 Antibody for Unresectable ICC
Sun Yat-sen University
Phase 2 Suspended
NCT01342653 2016-11-21
HIPEC
Hospital General Universitario Gregorio Marañon
Phase 2 Suspended
NCT01723306 2016-06-14
Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas
Roger Williams Medical Center
Phase 2 Suspended
NCT00609310 2012-02-03
Dietary Bioflavonoid Supplementation for the Prevention of Neoplasia Recurrence
Technische Universität Dresden
Phase 2 Suspended
NCT00568529 2010-05-26
Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer
Fudan University
Phase 2 Suspended
NCT00536770 2007-11-06
A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer
Novacea
Phase 2 Suspended
NCT00209664 2006-02-02
Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer
Hokkaido Gastrointestinal Cancer Study Group
Phase 2 Suspended
NCT00048529 2005-06-24
Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus
Tularik
Phase 2 Suspended